Actualités
WELCOME, Karen Winkworth
FORUS Therapeutics is thrilled to welcome Karen Winkworth as Therapeutic Area Manager, Hematology/Oncology, GTA. Karen brings with her a proven track record of delivering superior value across therapeutic areas - including over 15 years in hematology and oncology....
WELCOME, Chris Mitton
FORUS Therapeutics is delighted to welcome Chris Mitton as Therapeutic Area Manager, Hematology/Oncology, Atlantic Canada. Chris joins FORUS with over 30 years experience as a pharmaceutical professional with extensive expertise across various therapeutic areas,...
XPOVIO® Now Funded in Nova Scotia
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Nova Scotia as of October 1st. Please see the following link for full funding criteria: Nova Scotia Pharmacare News Bulletins Pharmacy Edition (novascotia.ca) We are excited...
La recommandation de l’INESSS de refuser le remboursement pour le traitement du myélome multiple fait figure d’exception au niveau mondial
In a remarkable decision posted earlier this month, INESSS stands alone in failing to recognize the therapeutic value of XPOVIO. This despite Health Canada approval, a positive CADTH decision, Quebec clinician and patient support and positive funding recommendations...
XPOVIO® Now Funded in PEI
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in PEI as of April 23rd. Please see the following links for full funding criteria: PEI Pharmacare Bulletin – Pharmacist Bulletin – April 09, 2024 We are excited about these...
XPOVIO® Now Funded in Ontario, Newfoundland and Labrador, and New Brunswick
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Ontario, Newfoundland and Labrador, and New Brunswick. Please see the following links for full funding criteria: Ontario: Exceptional Access Program | ontario.ca Newfoundland...
XPOVIO® Now Funded in British Columbia
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in British Columbia as of October 1, 2023. Further details on the criteria can be found here, under the MYBSD protocol: Lymphoma & Myeloma (bccancer.bc.ca) We are excited...
XPOVIO® Now Funded in Saskatchewan
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Saskatchewan as of September 1st. Please see the following link for full funding criteria: Drug Formulary (saskcancer.ca). We are excited about this important milestone for...
XPOVIO® Now Funded in Alberta
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Alberta as of June 5, 2023. Please see the following link for full funding criteria: AHS Outpatient Cancer Drug Benefit Program 2023-06-05 (albertahealthservices.ca). We are...
FORUS was a proud sponsor and participant in the Défi Cyclo-Myélome on May 27th, 2023
(Saint-lgnace-de-Stanbridge, Quebec) May 27th, 2023 – FORUS Therapeutics was a proud sponsor of the 11th Edition of the Défi Cyclo-Myélome. The Défi Cyclo-Myélome provides support to Dr. Richard LeBlanc, holder of the Université de Montréal Myeloma Canada Chair on...
FORUS Therapeutics Inc et l’Alliance pancanadienne pharmaceutique (APP) ont achevé les négociations concernant XPOVIO® (selinexor)
(OAKVILLE, Ontario) le 24 mai 2023 – FORUS Therapeutics Inc (« FORUS ») et l'Alliance pancanadienne pharmaceutique (« APP ») ont achevé les négociations d'une lettre d'intention concernant XPOVIOMD (sélinexor) en association avec le bortézomib et la dexaméthasone pour...
FORUS Therapeutics presented at the 2023 Bloom Burton & Co. Healthcare Investor Conference
(TORONTO, Ontario) April 25-26, 2023 – It was an honour to share the FORUS Therapeutics corporate update on April 25 at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto. We are very proud of the important commercialization milestones our team...